1. Home
  2. ENTX vs ANIX Comparison

ENTX vs ANIX Comparison

Compare ENTX & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • ANIX
  • Stock Information
  • Founded
  • ENTX 2010
  • ANIX 1982
  • Country
  • ENTX Israel
  • ANIX United States
  • Employees
  • ENTX N/A
  • ANIX N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • ANIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENTX Health Care
  • ANIX Health Care
  • Exchange
  • ENTX Nasdaq
  • ANIX Nasdaq
  • Market Cap
  • ENTX 90.2M
  • ANIX 82.7M
  • IPO Year
  • ENTX 2018
  • ANIX 1987
  • Fundamental
  • Price
  • ENTX $2.51
  • ANIX $3.01
  • Analyst Decision
  • ENTX Strong Buy
  • ANIX Strong Buy
  • Analyst Count
  • ENTX 1
  • ANIX 2
  • Target Price
  • ENTX $10.00
  • ANIX $8.50
  • AVG Volume (30 Days)
  • ENTX 84.8K
  • ANIX 142.6K
  • Earning Date
  • ENTX 03-07-2025
  • ANIX 03-11-2025
  • Dividend Yield
  • ENTX N/A
  • ANIX N/A
  • EPS Growth
  • ENTX N/A
  • ANIX N/A
  • EPS
  • ENTX N/A
  • ANIX N/A
  • Revenue
  • ENTX $99,000.00
  • ANIX N/A
  • Revenue This Year
  • ENTX N/A
  • ANIX N/A
  • Revenue Next Year
  • ENTX N/A
  • ANIX N/A
  • P/E Ratio
  • ENTX N/A
  • ANIX N/A
  • Revenue Growth
  • ENTX 607.14
  • ANIX N/A
  • 52 Week Low
  • ENTX $0.82
  • ANIX $2.07
  • 52 Week High
  • ENTX $3.35
  • ANIX $4.67
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 54.94
  • ANIX 59.42
  • Support Level
  • ENTX $2.00
  • ANIX $2.97
  • Resistance Level
  • ENTX $2.62
  • ANIX $3.25
  • Average True Range (ATR)
  • ENTX 0.19
  • ANIX 0.19
  • MACD
  • ENTX -0.00
  • ANIX 0.05
  • Stochastic Oscillator
  • ENTX 69.35
  • ANIX 70.83

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Share on Social Networks: